HOYA CORPORATION (HOCPY)
OTHER OTC:HOCPY
Top Page
HOYA
(OTC:HOCPY)
Select Model
Select Model
Rating:78Outperform
Price Target:
$211.00
▲(37.85% Upside)
Action:UpgradedDate:02/02/26
Score is driven primarily by strong financial performance (exceptional margins, very low leverage, and strong ROE). Technicals are supportive but somewhat overextended, while the overall rating is held back by a relatively high P/E and low dividend yield.
Positive Factors
High Profitability
Sustained, very high margins reflect durable pricing power and a premium product mix across optics and medical devices. High operating and net margins support reinvestment, R&D and resilience to cost shocks, underpinning long-term earnings quality and cash generation.
Negative Factors
Modest Top-line Growth
Recent revenue expansion is muted, indicative of a mature growth profile. Sustained low top-line growth increases reliance on margin expansion or M&A to drive EPS gains and limits organic upside, challenging long-term earnings acceleration.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability
Sustained, very high margins reflect durable pricing power and a premium product mix across optics and medical devices. High operating and net margins support reinvestment, R&D and resilience to cost shocks, underpinning long-term earnings quality and cash generation.
Read all positive factors
HOYA (HOCPY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$62.54B
Dividend Yield0.84%
Average Volume (3M)507.00
Price to Earnings (P/E)21.6
Beta (1Y)0.72
Revenue Growth9.79%
EPS Growth9.53%
CountryUS
Employees35,702
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)N/A
Shares Outstanding338,414,300
10 Day Avg. Volume0
30 Day Avg. Volume507
Financial Highlights & Ratios
PEG Ratio2.28
Price to Book (P/B)6.06
Price to Sales (P/S)6.66
P/FCF Ratio31.53
Enterprise Value/Market Cap149.46
Enterprise Value/Revenue10.08
Enterprise Value/Gross Profit12.21
Enterprise Value/Ebitda20.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HOYA Business Overview & Revenue Model
Company Description
HOYA Corporation is a Japanese multinational company that specializes in the manufacturing of optical products, including lenses for eyeglasses and cameras, as well as healthcare products and semiconductor-related materials. Established in 1941, H...
How the Company Makes Money
HOYA makes money by manufacturing and selling products in two broad areas: (1) Healthcare/optics and (2) Information technology/industrial components.
1) Vision care (eyeglass lenses and related optical products)
- Revenue model: Primarily produc...
HOYA Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
83
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 927.15B | 885.82B | 762.61B | 734.10B | 670.33B | 558.26B |
| Gross Profit | 765.40B | 766.25B | 421.69B | 631.86B | 567.28B | 474.98B |
| EBITDA | 451.54B | 310.00B | 285.70B | 259.78B | 243.96B | 200.27B |
| Net Income | 253.01B | 202.10B | 181.38B | 168.64B | 164.51B | 125.45B |
Balance Sheet | ||||||
| Total Assets | 1.31T | 1.23T | 1.20T | 1.03T | 992.84B | 853.29B |
| Cash, Cash Equivalents and Short-Term Investments | 580.98B | 538.53B | 525.16B | 426.27B | 426.63B | 338.79B |
| Total Debt | 41.46B | 37.28B | 29.24B | 24.58B | 21.60B | 20.75B |
| Total Liabilities | 264.40B | 262.65B | 241.36B | 213.72B | 203.78B | 180.88B |
| Stockholders Equity | 1.03T | 974.02B | 967.76B | 818.32B | 803.85B | 688.00B |
Cash Flow | ||||||
| Free Cash Flow | 153.05B | 187.19B | 181.73B | 168.36B | 161.18B | 120.57B |
| Operating Cash Flow | 194.99B | 235.11B | 222.80B | 201.83B | 190.06B | 151.81B |
| Investing Cash Flow | 8.07B | -33.19B | -35.81B | -47.50B | -29.30B | -29.79B |
| Financing Cash Flow | -214.81B | -190.35B | -110.89B | -194.59B | -106.72B | -115.67B |
HOYA Technical Analysis
Positive
153.06
Price Trends
176.34
Positive
165.26
Positive
151.22
Positive
Market Momentum
1.42
Negative
62.43
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOCPY, the sentiment is Positive. The current price of 153.06 is below the 20-day moving average (MA) of 175.16, below the 50-day MA of 176.34, and above the 200-day MA of 151.22, indicating a bullish trend. The MACD of 1.42 indicates Negative momentum. The RSI at 62.43 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HOCPY.
HOYA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $33.34B | 22.47 | 24.81% | 0.92% | 9.36% | 29.56% | |
78 Outperform | $62.54B | 21.59 | 25.14% | 0.84% | 9.79% | 9.53% | |
75 Outperform | $160.05B | 70.78 | 16.39% | ― | 22.18% | 21.37% | |
72 Outperform | $18.48B | 40.29 | 16.68% | 0.32% | 4.90% | -0.26% | |
68 Neutral | $43.91B | 28.46 | 6.93% | 2.13% | 8.23% | -2.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HOCPY
HOYA
182.79
76.74
72.36%
BDX
Becton Dickinson
155.43
-2.52
-1.59%
ISRG
Intuitive Surgical
458.96
-31.17
-6.36%
RMD
Resmed
230.26
17.64
8.30%
WST
West Pharmaceutical Services
259.96
48.04
22.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.